Velocity Clinical Research-Washington, DC

Washington D.C., District of Columbia 20016

4 studies enrolling now · 13 studies all time

What they study most

Acute Treatment of Migraine, COVID-19, Diabetic Peripheral Neuropathic Pain, Healthy Volunteers, Migraine, Pneumococcal Disease, RSV Infection, SARS-CoV-2, SARS-CoV-2 Infection, COVID-19, SARS-CoV-2 Virus, SARS-CoV2, Severe Acute Respiratory Syndrome Coronavirus 2

Studies at this site

• Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects — Recruiting now
• Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy — Recruiting now
• Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy — Recruiting now
• A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine — Recruiting now
• A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children — Completed
• A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults — Completed
• A Study to Learn About How a New Pneumococcal Vaccine Works in Infants — Running, not enrolling
• A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection — Running, not enrolling
• Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection — Stopped early
• Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children — Completed
• Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) — Running, not enrolling
• A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age — Completed